M Holdings Securities Inc. Buys Shares of 44,462 Bristol Myers Squibb Company $BMY

Posted by Stanley Muller on Jun 11th, 2026

M Holdings Securities Inc. bought a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 44,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,398,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. raised its position in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares during the period. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the second quarter valued at approximately $25,000. EQ Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $32,000. Garner Asset Management Corp purchased a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $35,000. Finally, Beacon Financial Strategies CORP purchased a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $55.62 on Thursday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The firm has a fifty day moving average price of $57.90 and a 200 day moving average price of $56.79. The company has a market cap of $113.58 billion, a P/E ratio of 15.62, a PEG ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on BMY. Piper Sandler restated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. HSBC boosted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Bank of America dropped their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $61.31.

Check Out Our Latest Report on BMY

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.